Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 7 (2010), Issue 9 (September)

1. Cost of walking, exertional dyspnoea and fatigue in individuals with multiple sclerosis not requiring assistive devices.
   J Rehabil Med, 42(8): 719-23. [Abstract] [Full-text]
2. Use of the International Classification of Functioning, Disability and Health to describe patient-reported disability: a comparison of Guillain Barré syndrome with multiple sclerosis in a community cohort.
   J Rehabil Med, 42(8): 708-14. [Abstract] [Full-text]
3. Natalizumab dosage suspension: are we helping or hurting?
   Ann Neurol, 68(3): 395-9. [Abstract] [Full-text]
4. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
   Ann Neurol, 68(3): 384-91. [Abstract] [Full-text]
5. Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
   Ann Neurol, 68(3): 392-5. [Abstract] [Full-text]
6. Safety and efficacy of natalizumab in children with multiple sclerosis.
   Neurology, 75(10): 912-7. [Abstract] [Full-text]
7. Association to the Glypican-5 gene in multiple sclerosis.
   J Neuroimmunol, 226(1): 194-7. [Abstract] [Full-text]
8. Two HLA class I genes independently associated with multiple sclerosis.
   J Neuroimmunol, 226(1): 172-6. [Abstract] [Full-text]
9. A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis.
   J Neuroimmunol, 226(1): 192-3. [Abstract] [Full-text]
10. Altered miRNA expression in T regulatory cells in course of multiple sclerosis.
    J Neuroimmunol, 226(1): 165-71. [Abstract] [Full-text]
11. Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.
    J Neuroimmunol, 226(1): 158-64. [Abstract] [Full-text]
12. Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.
    J Neuroimmunol, 226(1): 150-7. [Abstract] [Full-text]
13. Memory CD4+CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens.
    J Neuroimmunol, 226(1): 185-91. [Abstract] [Full-text]
14. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Clin Exp Immunol, 162(1): 1-11. [Abstract] [Full-text]
15. FLT-3 expression and function on microglia in multiple sclerosis.
    Exp Mol Pathol, 89(2): 109-16. [Abstract] [Full-text]
16. Natalizumab treatment reduces endothelial activity in MS patients.
    J Neuroimmunol, 227(1): 190-4. [Abstract] [Full-text]
17. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.
    J Neuroimmunol, 227(1): 185-9. [Abstract] [Full-text]
18. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis.
    J Neuroimmunol, 227(1): 162-6. [Abstract] [Full-text]
19. Long-term follow-up of neuromyelitis optica with a pediatric onset.
    Neurology, 75(12): 1084-8. [Abstract] [Full-text]
20. Symptom cluster and physical activity in relapsing-remitting multiple sclerosis.
    Res Nurs Health, 33(5): 398-412. [Abstract] [Full-text]
21. Distinguishing active from passive components of ankle plantar flexor stiffness in stroke, spinal cord injury and multiple sclerosis.
    Clin Neurophysiol, 121(11): 1939-51. [Abstract] [Full-text]
22. Exploring the effects of a 20-week whole-body vibration training programme on leg muscle performance and function in persons with multiple sclerosis.
    J Rehabil Med, 42(9): 866-72. [Abstract] [Full-text]
23. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis.
    J Neuropathol Exp Neurol, 69(10): 1017-33. [Abstract] [Full-text]
24. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.
    Neurology, 75(13): 1141-9. [Abstract] [Full-text]
25. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up.
    Neurology, 75(13): 1134-40. [Abstract] [Full-text]
26. How reproducible is home-based 24-hour ambulatory monitoring of motor activity in patients with multiple sclerosis?
    Arch Phys Med Rehabil, 91(10): 1537-41. [Abstract] [Full-text]
27. Demyelination versus remyelination in progressive multiple sclerosis.
    Brain, 133(10): 2983-98. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.